289 related articles for article (PubMed ID: 19046129)
1. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Ahrén B
Expert Opin Emerg Drugs; 2008 Dec; 13(4):593-607. PubMed ID: 19046129
[TBL] [Abstract][Full Text] [Related]
2. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Ahrén B
Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
4. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
9. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Green J; Feinglos M
Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
Hollander PA; Kushner P
Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Derosa G; Maffioli P
Diabetes Technol Ther; 2012 Apr; 14(4):350-64. PubMed ID: 22324384
[TBL] [Abstract][Full Text] [Related]
12. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):517-33. PubMed ID: 18054733
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
18. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
20. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
